Subbiah et al. (2016) have explored the use of the cellular mesenchymal–epithelial transition factor (c-Met)/ALK inhibitor crizotinib and the multi-kinase vascular endothelial growth factor (VEGF) inhibitor pazopanib in metastatic gastrointestinal neuroectodermal tumor (GNET) with EWSR1::CREB1 fusion. The gene discussed is VEGFA; the disease is gastric neuroendocrine tumor, well differentiated, low or intermediate grade.